RE: Chart take off14 Mar 2026 12:03
Alde,
Maybe the interim trial results are not that widely share under NDAs. This is Grok’s view:
Yes, pharmaceutical companies do share or release certain clinical trial data early under non-disclosure agreements (NDAs, also called confidential disclosure agreements or CDAs), though this is typically limited, targeted, and not the same as broad public release.
This practice occurs in specific contexts within the industry, primarily to protect proprietary, competitive, or sensitive information while enabling necessary collaborations or evaluations. Here's a breakdown based on standard industry practices:
Before engaging clinical trial sites: Sponsors (pharma companies or CROs) routinely require sites (e.g., hospitals, universities, or investigators) to sign an NDA/CDA before sharing the full trial protocol, investigator brochure, budget details, or other confidential documents. This happens during the site feasibility or selection process, well before the trial begins or data is generated. The goal is to protect scientific, commercial, or strategic information. Many academic institutions (like Stanford) and industry groups use standardized templates like the Accelerated Confidential Disclosure Agreement (ACDA) to streamline this.
In partnerships, licensing, or due diligence: Companies may share interim or early-phase data (e.g., during collaborations, mergers, acquisitions, or licensing deals) under strict NDAs. This allows potential partners to evaluate opportunities without public disclosure, preserving trade secrets and competitive advantages.
Interim data handling in ongoing trials: Interim results are often kept highly confidential to maintain trial integrity (e.g., avoiding bias or premature unblinding). Access is restricted to independent data monitoring committees (DMCs/DSMBs) under confidentiality obligations. Sponsors and investigators generally do not access full interim efficacy data unless pre-specified stopping rules are met. In rare cases, limited sharing might occur under confidentiality for safety reasons or regulatory interactions, but broad early release is avoided.
Not for general or public early release: Pharma companies do not typically release full trial data (e.g., results, raw datasets) early to the public or unrelated parties under NDAs. Instead:
Public transparency rules (e.g., FDAAA, ClinicalTrials.gov) require registration and eventual results posting/publication, often after trial completion or approval.
Voluntary data-sharing policies (e.g., from PhRMA/IFPMA members) allow qualified researchers to request patient-level or study data post-approval, sometimes with conditions, but not "early" during ongoing trials.
Full datasets or clinical study reports (CSRs) are submitted to regulators (FDA, EMA) but treated as confidential (with some exceptions for public access post-approval in certain jurisdictions).
Sign In
Follow the stocks
